Verastem, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Verastem, Inc. (VSTM) on June 16, 2026, covering events reported on June 16 and June 17, 2026. The filing focuses on clinical trial updates for the company's oncology pipeline, specifically targeting metastatic pancreatic ductal carcinoma (mPDAC).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure regarding clinical progress rather than a financial statement.
Material Changes and Clinical Updates
- RAMP 205 Trial Update: Announced positive updated safety and efficacy results for the combination of avutometinib plus defactinib with standard-of-care chemotherapy (gemcitabine and nab-paclitaxel) in first-line mPDAC.
- Key Efficacy Data (29 patients at RP2D):
- 6-month Overall Survival Rate: 86%
- 6-month Progression-Free Survival Rate: 68%
- Confirmed Objective Response Rate: 52%
- Tumor Shrinkage: 83% of patients
- Safety Profile: Adverse events were consistent with the previously reported profile with no new safety signals observed.
- TARGET-D 201 Trial Initiation: The first patient was dosed on June 16, 2026, in a Phase 2 registration-directed trial evaluating VS-7375 (an oral KRAS G12D inhibitor) as monotherapy and in combination with cetuximab for second-line mPDAC.
Guidance, Outlook, and Risks
Management commentary highlights the clinical activity of the avutometinib/defactinib combination and the initiation of the registration-directed trial for VS-7375. The filing does not contain specific financial guidance or updated risk factors beyond the inherent risks of clinical development. The data cutoff for the RAMP 205 results was June 5, 2026, with a median follow-up of 9.8 months.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for detailed statistical analysis and confidence intervals regarding the RAMP 205 results.
- Confirm the enrollment status and projected timeline for the TARGET-D 201 Phase 2 trial.
- Review the company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K does not contain financial data.
- Monitor regulatory feedback on the RP2D dose levels and the design of the registration-directed trial.